A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Authors
Starling, NVázquez-Mazón, F
Cunningham, D
Chau, I
Tabernero, J
Ramos, F
Iveson, T
Saunders, Mark P
Aranda, E
Countouriotis, A
Ruiz-Garcia, A
Wei, G
Tursi, J
Guillen-Ponce, C
Carrato, A
Affiliation
Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, London and Sutton, UK.Issue Date
2012-01
Metadata
Show full item recordAbstract
This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC).Citation
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. 2012, 23 (1):119-27 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdr046PubMed ID
21447616Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdr046
Scopus Count
Collections
Related articles
- Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
- Authors: Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, Bondarenko I, Jonker DJ, Sun Y, De la Cruz JA, Williams JA, Korytowsky B, Christensen JG, Lin X, Tursi JM, Lechuga MJ, Van Cutsem E
- Issue date: 2013 Apr 1
- First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
- Authors: Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y, Mizutani N, Hashigaki S, Lechuga MJ, Denda T
- Issue date: 2012 Aug
- A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
- Authors: Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC
- Issue date: 2012 Jul
- A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
- Authors: Yoshino T, Yamazaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayama M, Fujino T, Ohtsu A
- Issue date: 2013 Aug
- Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
- Authors: Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW
- Issue date: 2018 May